The ASCEND trial evaluated the safety, tolerability, and efficacy of solengepras and aimed to establish its potential to ...
The pivotal, Phase III study will evaluate the change in average daily “OFF” time in solengepras patients compared to placebo ...
Cerevance’s attempt to unlock the first-line Parkinson's disease market has hit a snag, with solengepras performing no better ...
This investigational treatment was generally well tolerated with no serious adverse events; fewer adverse events related to non-motor symptoms were reported in the solengepras arm Pivotal Phase 3 ...
UK-based clinical-stage biopharmaceutical company Cerevance has announced top-line results from the Phase II ASCEND trial of solengepras as an investigational monotherapy in patients with early, ...
Clinical Trials Arena on MSN23h
Arvinas’ PROTAC halves protein suspected to play role in Parkinson’sThe Phase I trial saw repeated oral doses of ARV-102 able to more than half the protein suspected to play a factor in ...
MedPage Today on MSN3d
Sleep and Alzheimer's; Daylight Saving Time Evidence; Woman Who Smells Parkinson'sSleep deficiency was associated with atrophy of the inferior parietal region, which is observed in early Alzheimer's disease. (Journal of Clinical Sleep Medicine) Researchers assessed evidence ...
Cerevance said. The European Medicines Agency rejected marketing authorization of donanemab (Kisunla) for Alzheimer's disease, saying the anti-amyloid drug's benefits do not outweigh its risks of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback